Aadi Biosciences News

Aadi Biosciences | 10-Q: Quarterly report

SEC05:14 · Announcements

Aadi Bioscience Remains Actively Engaged In A Comprehensive Strategic Review To Maximize Shareholder Value

BenzingaNov 6 21:05

Aadi Bioscience Is Completing Wind-down Of PRECISION1 Trial Of Nab-sirolimus In Patients With Solid Tumors Harboring TSC1 Or TSC2 Inactivating Alterations

BenzingaNov 6 21:04

Aadi Bioscience GAAP EPS of -$0.46 In-line, Revenue of $7.21M Beats by $0.61M

Seeking AlphaNov 6 21:03

Aadi Bioscience 3Q Loss/Shr 46c >AADI

Dow JonesNov 6 21:03

Earnings Flash (AADI) AADI BIOSCIENCE Reports Q3 Revenue $7.2M

MT NewswiresNov 6 21:01

Express News | Aadi Bioscience Q3 Operating Expenses USD 20.625 Million

BreakingsNov 6 21:00

Express News | Aadi Bioscience Q3 Product Sales USD 7.212 Million

BreakingsNov 6 21:00

Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update

PR NewswireNov 6 21:00

Calendar of U.S. Earnings Expected in the Week Ahead

Dow JonesNov 6 19:00

Earnings Preview: AADI to Report Financial Results on November 06

$Aadi Biosciences(AADI.US)$ is scheduled to release its financial results on November 06 ET. Earnings PreviewAnalysts estimate $Aadi Biosciences(AADI.US)$ to post revenue of USD6.60M for 2024Q3, up 10

Futu NewsNov 1 09:00

Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update

PR NewswireOct 31 04:05

The Arbitration Panel Issued A Final Award Which Found And Concluded That Aadi Bioscience Did Not Breach The EOC Pharma License Agreement And Accordingly Is Not Liable For Any Damages To EOC - Filing

BenzingaSep 30 18:17

Aadi Bioscience Downgraded to Neutral, Shares Fall

Seeking AlphaAug 28 00:20

Aadi Bioscience Price Target Cut to $1.75/Share From $5.00 by Piper Sandler

Dow JonesAug 27 22:57 · Ratings

Piper Sandler Downgrades Aadi Biosciences(AADI.US) to Hold Rating, Cuts Target Price to $1.75

Piper Sandler analyst Joseph Catanzaro downgrades $Aadi Biosciences(AADI.US)$ to a hold rating, and adjusts the target price from $5 to $1.75.According to TipRanks data, the analyst has a success

Futu NewsAug 27 17:32 · Ratings

Piper Sandler Downgrades Aadi Bioscience to Neutral From Overweight

MT NewswiresAug 27 17:16

Express News | Aadi Bioscience Inc : Piper Sandler Cuts to Neutral From Overweight

BreakingsAug 27 15:36

Express News | Aadi Bioscience Inc - Desai Will Continue to Serve as a Member of Board

BreakingsAug 23 04:18

Express News | Aadi Bioscience Inc - Board Has Determined That Itri's Pending Cessation of Employment Is a Voluntary Resignation

BreakingsAug 23 04:18